Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor-F Mautner

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
International Journal of Oncology|October 8, 2005
Overexpression of Midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potencyCarsten Friedrich, Nikola Holtkamp, Jindrich Cinatl, et al.
European Radiology|October 8, 2013
18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-offJohannes Salamon, Simon Veldhoen, Ivayla Apostolova, et al.
American Journal of Medical Genetics. Part A|April 23, 2015
Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1Kimberly Jett, Rosa Nguyen, Darian Arman, et al.
Neuro-Oncology|July 25, 2008
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapyNikola Holtkamp, Elke Malzer, Jan Zietsch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2012
Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1Johannes Salamon, Thorsten Derlin, Peter Bannas, et al.
American Journal of Medical Genetics. Part A|March 26, 2014
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisVanessa L Merker, Miriam A Bredella, Wenli Cai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2006
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumoursWinfried Brenner, Reinhard E Friedrich, Karim A Gawad, et al.
Journal of Neuro-Oncology|November 19, 2009
Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft modelMaria Demestre, Jan Herzberg, Nikola Holtkamp, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|June 19, 2016
Recurrent multilocular mandibular giant cell granuloma in neurofibromatosis type 1: Evidence for second hit mutation of NF1 gene in the jaw lesion and treatment with curettage and bone substitute materialsReinhard E Friedrich, Tobias J Grob, Silke Hollants, et al.
Neuro-Oncology|April 15, 2022
Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1Inka Ristow, Frederic Madesta, Lennart Well, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
International Journal of Oncology|October 8, 2005
Overexpression of Midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potencyCarsten Friedrich, Nikola Holtkamp, Jindrich Cinatl, et al.
European Radiology|October 8, 2013
18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-offJohannes Salamon, Simon Veldhoen, Ivayla Apostolova, et al.
American Journal of Medical Genetics. Part A|April 23, 2015
Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1Kimberly Jett, Rosa Nguyen, Darian Arman, et al.
Neuro-Oncology|July 25, 2008
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapyNikola Holtkamp, Elke Malzer, Jan Zietsch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2012
Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1Johannes Salamon, Thorsten Derlin, Peter Bannas, et al.
American Journal of Medical Genetics. Part A|March 26, 2014
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisVanessa L Merker, Miriam A Bredella, Wenli Cai, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 13, 2006
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumoursWinfried Brenner, Reinhard E Friedrich, Karim A Gawad, et al.
Journal of Neuro-Oncology|November 19, 2009
Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft modelMaria Demestre, Jan Herzberg, Nikola Holtkamp, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|June 19, 2016
Recurrent multilocular mandibular giant cell granuloma in neurofibromatosis type 1: Evidence for second hit mutation of NF1 gene in the jaw lesion and treatment with curettage and bone substitute materialsReinhard E Friedrich, Tobias J Grob, Silke Hollants, et al.
Neuro-Oncology|April 15, 2022
Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1Inka Ristow, Frederic Madesta, Lennart Well, et al.
Pageof 8